542 related articles for article (PubMed ID: 15121300)
41. Role of systemic and mucosal immune responses in reciprocal protection against Bordetella pertussis and Bordetella parapertussis in a murine model of respiratory infection.
Watanabe M; Nagai M
Infect Immun; 2003 Feb; 71(2):733-8. PubMed ID: 12540552
[TBL] [Abstract][Full Text] [Related]
42. Modified intra-cerebral challenge assay for acellular pertussis vaccines: comparisons among whole cell and acellular vaccines.
Gaines-Das R; Horiuchi Y; Zhang SM; Newland P; Kim Y; Corbel M; Xing D
Vaccine; 2009 Nov; 27(49):6824-32. PubMed ID: 19765397
[TBL] [Abstract][Full Text] [Related]
43. Aerosol infection test for evaluation of pertussis vaccine.
Syukuda Y; Watanabe H; Suehara A; Fujii S; Kuno-Sakai H; Kimura M
Tokai J Exp Clin Med; 1988; 13 Suppl():71-7. PubMed ID: 2908529
[TBL] [Abstract][Full Text] [Related]
44. Antibody responses in adult and neonatal BALB/c mice to immunization with novel Bordetella pertussis vaccine formulations.
Gracia A; Polewicz M; Halperin SA; Hancock RE; Potter AA; Babiuk LA; Gerdts V
Vaccine; 2011 Feb; 29(8):1595-604. PubMed ID: 21215343
[TBL] [Abstract][Full Text] [Related]
45. [Efficacy of acellular pertussis vaccines].
Wirsing von König CH; Finger H
Immun Infekt; 1995 Aug; 23(4):125-9. PubMed ID: 7558115
[TBL] [Abstract][Full Text] [Related]
46. Outer membrane vesicles as acellular vaccine against pertussis.
Roberts R; Moreno G; Bottero D; Gaillard ME; Fingermann M; Graieb A; Rumbo M; Hozbor D
Vaccine; 2008 Aug; 26(36):4639-46. PubMed ID: 18640169
[TBL] [Abstract][Full Text] [Related]
47. Determination of serum antibody to Bordetella pertussis adenylate cyclase toxin in vaccinated and unvaccinated children and in children and adults with pertussis.
Cherry JD; Xing DX; Newland P; Patel K; Heininger U; Corbel MJ
Clin Infect Dis; 2004 Feb; 38(4):502-7. PubMed ID: 14765342
[TBL] [Abstract][Full Text] [Related]
48. Pertussis: persistent pathogen, imperfect vaccines.
Yeh SH
Expert Rev Vaccines; 2003 Feb; 2(1):113-27. PubMed ID: 12901603
[TBL] [Abstract][Full Text] [Related]
49. Parapertussis and pertussis: differences and similarities in incidence, clinical course, and antibody responses.
Bergfors E; Trollfors B; Taranger J; Lagergård T; Sundh V; Zackrisson G
Int J Infect Dis; 1999; 3(3):140-6. PubMed ID: 10460925
[TBL] [Abstract][Full Text] [Related]
50. Bordetella pertussis, B. parapertussis, vaccines and cycles of whooping cough.
Bouchez V; Guiso N
Pathog Dis; 2015 Oct; 73(7):. PubMed ID: 26242280
[TBL] [Abstract][Full Text] [Related]
51. IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: effect of vaccine antigen content.
Hendrikx LH; Berbers GA; Veenhoven RH; Sanders EA; Buisman AM
Vaccine; 2009 Nov; 27(47):6530-6. PubMed ID: 19729085
[TBL] [Abstract][Full Text] [Related]
52. Bordetella pertussis and pertussis vaccines.
Guiso N
Clin Infect Dis; 2009 Nov; 49(10):1565-9. PubMed ID: 19839747
[TBL] [Abstract][Full Text] [Related]
53. Pertussis-specific cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine.
Edelman KJ; He Q; Makinen JP; Haanpera MS; Tran Minh NN; Schuerman L; Wolter J; Mertsola JA
Clin Infect Dis; 2004 Jul; 39(2):179-85. PubMed ID: 15307026
[TBL] [Abstract][Full Text] [Related]
54. Evolution of French Bordetella pertussis and Bordetella parapertussis isolates: increase of Bordetellae not expressing pertactin.
Hegerle N; Paris AS; Brun D; Dore G; Njamkepo E; Guillot S; Guiso N
Clin Microbiol Infect; 2012 Sep; 18(9):E340-6. PubMed ID: 22717007
[TBL] [Abstract][Full Text] [Related]
55. Pertussis vaccination and whooping cough: and now what?
Guiso N
Expert Rev Vaccines; 2014 Oct; 13(10):1163-5. PubMed ID: 25020131
[TBL] [Abstract][Full Text] [Related]
56. Local and systemic immune responses to pertussis infection and cellular and acellular vaccines.
Ashworth LA; Day A; Lambert HP; Lingham S; Lissauer T; Miller E; Robinson A; Rutter DA; Thomas MG
Ann Sclavo Collana Monogr; 1986; 3(1-2):199-211. PubMed ID: 2892507
[No Abstract] [Full Text] [Related]
57. Risk factors for acellular and whole-cell pertussis vaccine failure in Senegalese children.
Lacombe K; Yam A; Simondon K; Pinchinat S; Simondon F
Vaccine; 2004 Dec; 23(5):623-8. PubMed ID: 15542182
[TBL] [Abstract][Full Text] [Related]
58. Serologic response and antibody-titer decay in adults with pertussis.
Heininger U; Cherry JD; Stehr K
Clin Infect Dis; 2004 Feb; 38(4):591-4. PubMed ID: 14765356
[TBL] [Abstract][Full Text] [Related]
59. Protective activity of the Bordetella pertussis BrkA autotransporter in the murine lung colonization model.
Marr N; Oliver DC; Laurent V; Poolman J; Denoël P; Fernandez RC
Vaccine; 2008 Aug; 26(34):4306-11. PubMed ID: 18582518
[TBL] [Abstract][Full Text] [Related]
60. Comparison of toxicities of acellular pertussis vaccine with whole cell pertussis vaccine in experimental animals.
Sato Y; Sato H
Dev Biol Stand; 1991; 73():251-62. PubMed ID: 1778317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
